鄧務國:人物經歷,研究方向,主要成就,發表論文,已發表的國際學術會議摘要,在美國參

鄧務國，男，博士, 教授，博士生導師，中山大學“百人計畫”引進人才，現為中山大學腫瘤防治中心華南腫瘤學國家重點實驗室教授，PI和博士生導師。

基本介紹

中文名：鄧務國
國籍：中國
畢業院校：北京大學
職業：博士生導師
工作單位：華南腫瘤學國家重點實驗室

人物經歷,研究方向,主要成就,發表論文,已發表的國際學術會議摘要,在美國參加的國際學術會議及所作的學術報告,

人物經歷

1997年在北京大學獲得理學博士學位 (專業：生物化學和套用化學)。博士期間, 主要從事黃酮類天然藥物抗氧化活性及其與自由基反應機制的研究。1997-1998年, 在中國人民大學化學教研室任講師。1998-2003年, 在美國德克薩斯大學休斯敦醫學院 (The University of Texas Health Science Center Medical School in Houston) 從事博士後研究, 主要進行與炎症和腫瘤相關基因(COX-2/iNOS)的表達調控和分子機制等生物醫學領域的研究工作。2003-2009年被聘任到美國排名第一的癌症研究和臨床治療中心-德克薩斯大學M.D.安得森癌症中心 (TheUniversity of Texas M.D. Anderson Cancer Center)工作, 先後任講師(Instructor)和助理教授 (Assistant Professor), 主要從事肺癌、皮膚癌、乳腺癌的基因治療和靶向治療; 抗癌基因 (FUS1和 IL24) 的作用機制和信號傳導，以及新型腫瘤分子標記和藥物治療靶點等方面的研究, 並指導博士生和博士後的科研工作。2008年至今，被聘為浙江大學客座教授。2009年9月，作為中山大學“百人計畫”人才引進回國，任中山大學腫瘤防治中心華南腫瘤學國家重點實驗室教授，PI和博士生導師。

研究方向

（1）肺癌、皮膚癌和乳腺癌的發生、發展和轉移的信號傳導及分子機理

（2）癌症的基因治療, 分子靶向治療和結合治療,以及這些治療的分子機制和臨床套用

（3）抗癌基因 (如FUS1, IL-24, NPRL2, FHIT，p53) 和致瘤基因 (如COX-2，iNOS，AP-2β, CD70) 的表達調控、信號轉導和分子機制

（4）利用最近發展的基因組學和蛋白質組學技術 (如PCR Array, siRNA library screen, SELID-MS and LC-MS-based Protein Chip Arrays) 篩選,發現和鑑定新型的腫瘤分子標記和藥物治療靶點

（5）新型多功能抗癌納米藥物 (基因納米藥物和多肽納米藥物) 的研究開發, 以及它們在癌症治療和檢測上的臨床套用

主要成就

以第一作者在Blood, Cancer Research, J Biol Chem, The FASEB Journal, Oncogene, Journal of Immunology, Melanoma Research, Cancer Gene Therapy, Circulation等國際主流雜誌上發表論文多篇, 以第一作者發表高水平論文多篇。先後獨力或共同申請主持美國 NIH/NCI 研究項目 (SPORE, R01, P01) 六項。是FASEB Journal, Cellular and Molecular Biology Letter, Experimental Lung Research 等雜誌的審稿人; 美國癌症研究協會 (AACR)、美國生物化學和分子生物學 (ASBMB) 會員。

發表論文

1. Deng WG, Kwon J, Ekmekcioglu S, Poindexter NJ, Grimm EA. IL-24 gene transfer sensitizes melanoma cells to erlotinib through modulation of the Apaf-1 and Akt signaling pathway. Melanoma Res. (in press), 2009.

2. Deng WG, Wu G, Ueda K, Xu K, Roth JA, Ji L. Enhancement of antitumor activity of cisplatin by tumor suppressor FUS1 in human lung cancer cells. Cancer Gene Ther. 15:29-39, 2008.

3. Deng WG, Kawashima H, Wu G, Jayachandran J, Xu K, Minna JD, Roth JA, Ji L. Synergistic tumor suppression by coexpression of FUS1 and p53 is associated with downregulation of MDM2 and activation of Apaf1-dependent apoptotic pathway in human non-small cell lung cancer cells. Cancer Res. 67:709-17, 2007.

4. Deng WG, Montero A, Wu KK. Interferon-gamma suppresses COX-2 promoter activity by inhibiting c-Jun and C/EBP? binding. Arterioscler. Thromb. Vasc. Biol. 27:1752-1759, 2007.

5. Deng WG, Jayachandran G, Xu K, Roth JA, Ji L. Tumor-specific activation of human telomerase reverse transcriptase (hTERT) promoter activity by activating enhancer-binding protein-2? (AP-2?) in human lung cancer cells. J. Biol. Chem. 282:26460-70, 2007.

6. Deng WG, Nishizaki M, Kagawa S, Fang B, Roth JA, Ji L. Induction of apoptosis by FHIT gene via activation of death receptor and caspase cascade signaling pathway in human non-small lung cancer cells. Biochem. Biophys. Res. Commun. 355:993-999, 2007.

7. Lin J, Sun T, Ji L, Deng W, Roth JA, Minna J, Arlinghaus R. Oncogenic activation of c-Abl in non-small cell lung cancer cells lacking FUS1 expression: Inhibition of c-Abl by the tumor suppressor gene product Fus1. Oncogene 26:6989-96, 2007.

8. Ohtani S, Ueda K, Deng W, Wu G, Jayachandran G, Iwamaru A, Kondo S, Atkinson EN, Minna JD, Roth JA, Ji L. A combination treatment with candidate 3p21.3 tumor suppressor 101F6-nanoparticle and ascorbic acid promotes synergistic and selective inhibition of human NSCLC growth via caspase-independent apoptosis and autophagic cell death. Cancer Res. 67:6293-6303, 2007.

9. Deng WG, Tang SZ, Tseng HP, Wu KK. Melatonin suppresses macrophage cyclooxygenase-2 and inducible nitric oxide synthase expression by inhibiting p52 acetylation and binding. Blood 108:518-24, 2006.

10. *Cieslik KA, *Deng WG, (*co-first author), Wu KK. Essential role of C-Rel in nitric oxide synthase-2 transcriptional activation: time-dependent control by salicylate. Mol. Pharmacol. 70:2004-14, 2006

11. Ueda K, Kawashima H, Ohtani S, Deng W, Ravoori M, Bankson J, Gao B, Girard L, Minna JD, Roth JA, Kundra V, Ji L. The 3p21.3 Tumor suppressor NPRL2 plays an important role in cisplatin-induced resistance in human non-small-cell lung cancer cells. Cancer Res. 66:9682-90, 2006.

12. Deng WG, Zhu Y, Wu KK. Role of p300 and PCAF in regulating cyclooxygenase-2 promoter activation by inflammatory mediators. Blood 103: 2135-42, 2004.

13. Deng WG, Zhu Y, Wu KK. Up-regulation of p300 binding and p50 acetylation in tumor necrosis factor-alpha induced cyclooxygenase-2 promoter activation. J. Biol. Chem. 278: 4770-77, 2003.

14. Deng WG, Wu KK. Regulation of nitric oxide synthase expression by p300 coactivator and p50 NF-?B acetylation. J. Immunol. 171:6581-88, 2003.

15. Deng WG, ZhuY, Montero A, Wu KK. Quantitative analysis of binding of transcription factor complex to biotinylated DNA probe by a treptavidin-agarose pulldown assay. Anal. Biochem. 323:12-8, 2003.

16. Deng WG, Saunders M, He XZ, Yeh H, Wu KK. Identification of cyclooxygenase-2 and angiogenesis suppressing factor produced by human fibroblasts. FASEB J. 16:1286-98, 2002.

17. Zhu Y, Saunders M, Yeh H, Deng WG, Wu KK. Dynamic regulation of cyclooxygenase-2 promoter activity by isoforms of CCAAT/enhancer-binding protein. J. Biol. Chem. 277:6923-28, 2002.

18. Schroer K, Zhu Y, Saunders M, Deng WG, Xu XM, Meyer-Kirchrath J, Wu, KK. Obligatory role of cyclic adenosine monophosphate response element in cyclooxygenase-2 promoter induction and feedback regulation by inflammatory mediators. Circulation 105:2760-65, 2002.

19. Deng WG, Ruan KH, Du M, Saunders M, Wu KK. Aspirin and salicylate bind to BiP and inhibit its ATPase activity in human fibroblasts. FASEB J. 15:2463-70, 2001.

20. *Liou JY, *Deng WG, (*co-first author), Gilroy DK, Wu KK. Colocalization and interaction of cyclooxygenase (COX-2) and caveolin-1 in human fibroblasts. J. Biol. Chem. 276:34975-82, 2001.

21. Deng WG, He YK, Fang XW, Wu JL. Radiolysis of rutin in aerated ethanolic solution. Radiat. Phys. Chem. 53:629-33, 1998.

22. Deng WG, Fang XW, Wu JL. Flavonoids function as antioxidants: by scavenging reactive oxygen species or by chelating iron? Radiat. Phys. Chem. 50:273-5, 1997.

23. Yi QM, Deng WG, Xia ZP. Polymorphism and genetic relationship among wild and cultivated rice species determined by AP-PCR analysis. Hereditas 122:135-41, 1995.

已發表的國際學術會議摘要

1. Deng W, Kwon J, Grimm, EA. Combination therapy with IL-24 and tyrosine kinase inhibitors: A new promising therapeutic strategies for the treatment of human melanoma. American Association for Cancer Research (AACR) 100th Annual Meeting, Denver, CO, April 18, 2009. Proc. Am. Assoc. Cancer Res. 50:820, 2009. 2. Deng W, Kawashima H, Roth JA, Ji L. Tumor suppressor FUS1 sensitizes response to gefitinib treatment and overcomes chemoresistance via inactivation of the AKT/MET signaling pathway in human lung cancer cells American Association for Cancer Research (AACR) 99th Annual Meeting, San Diego, CA, April 12-16, 2008. Proc. Am. Assoc. Cancer Res. 49: 2008.

3. Jayachandran G, Deng W, Minna JD, Roth JA, Ji L. Bystander effects in FUS1-nanoparticle-mediated human lung cancer gene therapy. American Association for Cancer Research (AACR) 99th Annual Meeting, San Diego, CA, April 12-16, 2008. Proc. Am. Assoc. Cancer Res. 49: 2008

4. Deng W, Uno F, Wu G, Kawashima H, Roth JA, Ji L. Nanoparticle-mediated delivery of therapeutic peptide derived from novel tumor suppressor FUS1 protein for human lung cancer treatment. American Association for Cancer Research (AACR) 98th Annual Meeting. Los Angeles, CA, April, 2007. Proc. Am. Assoc. Cancer Res. 48:1334, 2007.

5. Iwamaru A, Deng W, Kawashima H, Roth JA, Ji L Interaction of tumor suppressor FUS1 with nuclear receptor tyrosine kinase RAR-? proteins enhances the sensitivity of non-small cell lung cancer (NSCLC) to retinoid-mediated therapy. American Association for Cancer Research (AACR) 98th Annual Meeting. Los Angieles, CA, April, 2007. Proc. Am. Assoc. Cancer Res. 48:985, 2007.

6. Deng W, Jayachandran G, Xu K, Roth JA, Ji L. Tumor-specific activation of hTERT promoter activity by the AP-2 beta transcription factor in human lung cancer cells. American Association for Cancer Research (AACR) 97th Annual Meeting. Washington, DC, April, 2007. Proc. Am. Assoc. Cancer Res. 47:929, 2006.

7. Wu G, Deng W, Jayachandran G, Minna JD, Roth JA, Ji L. Interaction of the tumor suppressor FUS1 with PDGFR beta inhibits PDGFR-mediated proliferation of human lung cancer cells. American Association for Cancer Research (AACR) 97th Annual Meeting, Washington, DC, April, 2006. Proc. Am. Assoc. Cancer Res. 47:344, 2006.

8. Kawashima H, Jayachandran G, Deng W, Xu,K, Minna JD, Roth JA, Ji L. Overcoming gefitinib resistance in NSCLC via inactivation of the PI3K/AKT signaling pathway by a combination of the FUS1 nanoparticles and EGFR inhibitors. American Association for Cancer Research (AACR) 97th Annual Meeting, Washington, DC, April, 2007. Proc. Am. Assoc. Cancer Res. 47:1274, 2006.

9. Deng W, Uno F, Minna JD, Roth JA, Ji L. Synergistic tumor suppression by coexpression of FUS1 and p53 concurrences with FUS1-mediated down regulation of MDM2, accumulation of p53, and activation of Apaf1-dependent apoptotic pathway in human NSCLC cells. American Association for Cancer Research (AACR), 96th Annual Meeting, Anaheim, CA, April, 2005. Proc. Am. Assoc. Cancer Res. 46: 828, 2005.

10. Wu G, Deng W, Kundra V, Fang B, Roth JA, Ji L. A novel synthetic hTERT-Mini-CMV chimera promoter-driven tumor-selective and high-efficiency expression of transgene for systemic cancer gene therapy. American Association for Cancer Research (AACR), 96th Annual Meeting, Anaheim, CA, April, 2005. Proc. Am. Assoc. Cancer Res. 46:791, 2005.

11. Ueda K, Kawashima H, Deng W, Minna JD, Roth JA, Ji L. Inactivation of the potential 3p21.3 tumor suppressor NPRL2 significantly correlates with the cisplatin-induced resistance in human NSCLC cells. American Association for Cancer Research (AACR), 96th Annual Meeting, Anaheim, CA, April, 2005. Proc. Am. Assoc. Cancer Res. 46:350, 2005.

12. Deng W, Wu KK. Augmentation of NF-?B mediated gene expression by a positive p300 and p50 regulatory loop. The Experimental Biology (EB) 2003 Meeting Abstracts, San Deigo, CA, April, 2003.

13. Deng W, Wu KK. Role of p300 coactivator and histone acetyltransferase in COX-2 transcriptional activation. The 4th Winter Eicosanoid Conference Abstracts, Baltimore, MA, March, 2002.

14. Deng W, Shtivelband MI, Wu KK. Control of cancer-induced angiogenesis by an endogenous factor. The 44th American Society of Hematology Annual Meeting Abstracts, Philadephia, PA, December, 2002.

在美國參加的國際學術會議及所作的學術報告

1. Novel combination of IL-24 molecular therapy with tyrosine kinase inhibitors: A new promising therapeutic strategies for the treatment of human melanoma. The American Association for Cancer Research (AACR) 2009 100th Annual Meeting, Denver, CO, USA, April 18-22, 2009. (Poster)

2. IL-24/MDA-7 nanoparticles in combination with tyrosine kinase inhibitors enhances inhibition of human melanoma via Apaf-1 and Akt–dependent signaling pathways. The American Association for Cancer Research (AACR) Special Meeting: Infection and Cancer Therapeutics, Hong Kong, China, December 7-11, 2008. (Poster)

3. Combination treatment with FUS1 nanoparticles and EGFR inhibitors for lung cancer. The 99th American Association for Cancer Research (AACR) 2008 Annual Meeting, San Diego, CA, USA April 12-16, 2008. (Oral)

4. Bystander effects in FUS1-nanoparticle-mediated human lung cancer gene therapy. The 99th American Association for Cancer Research (AACR) 2008 Annual Meeting, San Diego, CA, USA April 12-16, 2008. (Poster)

5. Development of novel delivery systems for therapeutic peptide for human lung cancer treatment. The 98th American Association for Cancer Research (AACR) 2007 Annual Meeting, Los Angeles, CA, USA April 14-18, 2007. (Poster)

6. Interaction of tumor suppressor FUS1 with nuclear receptor tyrosine kinase RAR-? proteins. The 98th American Association for Cancer Research (AACR) 2007 Annual Meeting, Los Angeles, CA, USA, April 　14-18, 2007. (Oral)

7. Discovery of novel cancer biomarkers and therapeutic targets associated with hTERT promoter in human lung cancer cells. The 97th American Association for Cancer Research (AACR) Annual Meeting, Washington, DC, USA, April 1-5, 2006. (Oral)

8. Interaction of tumor suppressor Fus1 with PDGFR beta inhibits PDGFR-mediated proliferation of human lung cancer cells. The 97th American Association for Cancer Research (AACR) Annual Meeting, Washington, DC, USA, April 1-5, 2006. (Poster)

9. Overcoming gefitinib resistance in NSCLC via inactivation of the PI3K/AKT signaling pathway by a combination of FUS1 nanoparticles and EGFR inhibitors. The 97th American Association for Cancer Research (AACR) Annual Meeting, Washington, DC, USA, April 1-5, 2006. (Poster)

10. Synergistic tumor suppression by coexpression of FUS1 and p53 in human lung cancer cells. The 96th American Association for Cancer Research (AACR) Annual Meeting, Anaheim, CA, USA, April 16-20, 2005. (Poster)

11. A novel synthetic hTERT-Mini-CMV chimera promoter-driven tumor-selective and high-efficiency expression of transgene for systemic cancer gene therapy. The 96th American Association for Cancer Research (AACR) Annual Meeting, Anaheim, CA, USA, April 16-20, 2005. (Poster)

12. Inactivation of the potential 3p21.3 tumor suppressor NPRL2 significantly correlates with the cisplatin-induced resistance in human NSCLC cells. The 96th American Association for Cancer Research (AACR) Annual Meeting, Anaheim, CA, USA, April 16-20, 2005. (Oral)

13. Augmentation of NF-?B mediated gene expression by a positive p300 and p50 regulatory loop. The Experimental Biology (EB) 2003 Meeting, San Diego, CA, USA, April 11-15, 2003. (Poster)

14. Regulation of COX-2 and iNOS gene by p300 binding and NF-?B p50 acetylation. The Special Postdoctoral Program for American Society for Biochemistry and Molecular Biology (ASBMB) Travel Awardees at the Experiment Biology 2003 Meeting, San Diego, CA, USA, April 13, 2003. (Poster)

15. Control of cancer-induced angiogenesis by an endogenous factor. The 44th American Society of Hematology Annual Meeting, Philadelphia, PA, USA, December 7-10, 2002. (Oral)

16. Role of p300 coactivator and histone acetyltransferase in cyclooxygenase-2 transcriptional activation. The 4th Winter Eicosanoid Conference, Baltimore, ML, USA, March 10-13, 2002. (Oral)

鄧務國